All In Biotech

Drug Trial Radar · NCT07188844

An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

An Open-Label Extension Study to Assess Long-term Safety and Tolerability of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

26

Actual

Start

Aug 28, 2025

Primary completion

Jul 16, 2026

Study completion Jul 16, 2026

Sponsor

Lead sponsor
Immunovant Sciences GmbHIndustry
Sponsor type
Industry
First posted
Sep 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label extension (OLE) study designed to evaluate the long-term safety and tolerability of batoclimab in participants with CIDP who have completed Study IMVT-1401-2401 (NCT05581199). In this study, participants will receive 340 mg of batoclimab subcutaneously (SC) once weekly (QW) for up to 52 weeks. Upon completion of the Week 52 or early termination (ET) Visit, participants will transition into the 4-week Follow-up Period, which concludes with a Follow-up Visit approximately 28 (± 7) days after the Week 52 or ET Visit.

Conditions

  • Chronic Inflammatory Demyelinating Polyneuropathy

Interventions

  • BatoclimabDrug

    Batoclimab 340 mg SC QW

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment DiscontinuationTime frame: Up to 52 weeks

Locations

30 sites in 11 countries. Site status is shown where the registry gives one.

  • Site Number - 1621

    New Haven, Connecticut

  • Site Number - 1617

    Ormond Beach, Florida

  • Site Number - 1611

    Nicholasville, Kentucky

  • Site Number - 1610

    Charlotte, North Carolina

  • Site Number - 1601

    Austin, Texas

  • Site Number - 7750

    Buenos Aires, Argentina

  • Site Number - 7752

    San Miguel de Tucumán, Argentina

  • Site Number - 7753

    Rosario, Santa Fe Province, Argentina

  • Site Number - 7751

    Rosario, Santa Fe Province, Argentina

  • Site Number - 4680

    Leuven, Vlaams Brabant, Belgium

  • Site Number - 9103

    Brasília, Federal District, Brazil

  • Site Number - 9101

    Curitiba, Paraná, Brazil

  • Site Number - 9100

    Ribeirão Preto, São Paulo, Brazil

  • Site Number - 6702

    Leipzig, Saxony, Germany

  • Site Number - 6347

    Larissa, Greece

  • Site Number - 6341

    Pátrai, Achaïa, Greece

  • Site Number - 6344

    Athens, Attica, Greece

  • Site Number - 6305

    Bologna, Emilia-Romagna, Italy

  • Site Number - 6309

    Rome, Lazio, Italy

  • Site Number - 6307

    Milan, Lombardy, Italy

  • Site Number - 3207

    Poznan, Greater Poland Voivodeship, Poland

  • Site Number - 3208

    Krakow, Lesser Poland Voivodeship, Poland

  • Site Number - 3209

    Krakow, Lesser Poland Voivodeship, Poland

  • Site Number - 3210

    Lublin, Lublin Voivodeship, Poland

  • Site Number - 3206

    Lublin, Lublin Voivodeship, Poland

  • Site Number - 3201

    Katowice, Silesian Voivodeship, Poland

  • Site Number - 8400

    Constanța, Romania

  • Site Number - 8403

    Timișoara, Timiș County, Romania

  • Site Number - 8501

    Belgrade, Serbia

  • Site Number - 8603

    Prešov, Slovakia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.